Abstract: Provided is a method for producing semiconductor nanoparticles. The method includes: providing first semiconductor nanoparticles containing a semiconductor containing an element M1, an element M2 and an element Z, wherein the element M1 is at least one element selected from the group consisting of Ag, Cu, Au and an alkali metal, and contains at least Ag, the element M2 is at least one element selected from the group consisting of Al, Ga, In and Tl, and contains at least one of In and Ga, and the element Z contains at least one element selected from the group consisting of S, Se and Te; and heat-treating a mixture containing the first semiconductor nanoparticles, a first compound having a Ga—S bond, a second compound containing Ga and not containing S, and an organic solvent to obtain second semiconductor nanoparticles.

Abstract: An aspect of the present invention is a gas treatment method including: an absorption step of bringing a gas to be treated, which contains carbon dioxide and a sulfur compound, into contact with an absorption liquid to be phase-separated by carbon dioxide absorption, to cause the absorption liquid to absorb the carbon dioxide and the sulfur compound; and a first release step of heating the absorption liquid brought into contact with the gas to be treated to a temperature equal to or higher than a temperature at which the carbon dioxide absorbed by the absorption liquid is released from the absorption liquid and lower than a temperature at which the sulfur compound absorbed by the absorption liquid is released from the absorption liquid, to release the carbon dioxide from the absorption liquid.

Abstract: There is provided a method for efficient differentiation induction from human pluripotent stem cells into hypothalamic neurons. Also, provided is a method for constructing, from human pluripotent stem cells, a cellular structure in which hypothalamic tissue and pituitary tissue are integrated. A cellular structure including hypothalamic tissue is obtained by a method including the steps of: culturing an aggregate of human pluripotent stem cells in suspension in a medium containing a low concentration of a bone morphogenetic protein signal transduction pathway activating substance and a low concentration of a substance acting on the Shh signaling pathway; and further culturing the cell aggregate obtained in the step in suspension in a medium containing a low concentration of a substance acting on the Shh signaling pathway.

Abstract: The gas measurement device includes a filter having a plurality of openings, each opening being variable in size, an adjustment mechanism configured to vary size of the plurality of openings, a first gas sensor configured to detect gas molecules passing through an opening of the filter and output a first measurement value corresponding to the detected gas molecules, and a second gas sensor configured to detect the gas molecules passing through the opening of the filter, output a second measurement value corresponding to the detected gas molecules, and detect gas molecules of a gas species different from the gas molecules detected by the second gas sensor.

Abstract: An object of the present invention is to provide a method capable of detecting whether a subject has systemic lupus erythematosus (preferably nephrotic syndrome) with high accuracy without performing a renal biopsy, a biomarker for carrying out such detection, and the like. The concentration of 3?,4?-didehydro-3?-deoxycytidine in urine collected from a test subject is measured, and this concentration is compared with a reference concentration for control, which allows to detect whether the above-mentioned test subject has systemic lupus erythematosus (preferably lupus nephritis) with high accuracy.

Abstract: The present invention addresses the problem of providing a lipid nanoparticle in which a nucleic acid, etc., required in genome editing is encapsulated and which can be produced by an alcohol dilution method using flow channels and contributes to high genome editing efficiency. The present invention pertains to a lipid nanoparticle which comprises a lipid component, a DNA nuclease, a guide RNA and a single-stranded oligonucleotide, wherein: the lipid component comprises a pH-sensitive cationic lipid, a neutral phospholipid and a polyalkylene glycol-modified lipid; the ratio of the pH-sensitive cationic lipid relative to the total lipids constituting the lipid nanoparticle is 30-50 mol %; the ratio of the neutral phospholipid relative to the total lipids constituting the lipid nanoparticle is 20-50 mol %; and the ratio of the polyalkylene glycol-modified lipid relative to the total lipids constituting the lipid nanoparticle is 1-4 mol %.

Abstract: There is provided a light detecting device including: a laser light source generating light source pulse beam; a splitting section splitting the light source pulse beam into excitation beam, first probe beam and second probe beam; a first modulating section executing optical path length modulation that modulates a relative optical path length difference between the excitation beam, and the first probe beam and the second probe beam; a second modulating section phase-modulating the first probe beam; and a detecting section illuminating combined beam, in which the excitation beam, the first probe beam and the second probe beam are multiplexed, onto a sample, and detecting a stimulated Raman scattering signal that is generated.

Abstract: A radial flux synchronous machine includes a stator in a cylindrical shape provided with a plurality of magnetic poles, an inner rotor disposed radially inward of the stator and having an inner armature opposing the magnetic pole from radially inward, and an outer rotor disposed radially outward of the stator and having an outer armature opposing the magnetic pole (from radially outward.

Abstract: A method of pretreating a blood sample for measuring ATP of a pathogenic microorganism in blood, comprising: preparing a pellet of platelets and the pathogenic microorganism from the blood sample; and subjecting the pellet of platelets and the pathogenic microorganism to the following steps (A) to (C) in any order (including multiple simultaneous steps). A method of pretreating a cultured blood sample, wherein the method is a simplified method, does not comprise the following step (A), and comprises the steps (B) and (C) only simultaneously performed. (A) digesting cell membrane proteins of the platelets with a protease; (B) swelling the platelets in a hypotonic solution; and (C) disrupting cell membranes of the platelets with a detergent solution under a condition of suppressing an effect on the pathogenic microorganism.

Abstract: A column 2 is provided in a gas capturing unit 20 for capturing sample gas. A gas supply unit 1 supplies carrier gas for sending sample gas into the column 2. A gas separation mechanism 100 guides carrier gas in the column 2 to the outside of the column 2 by setting the lead-out path 5 to negative pressure with respect to the inside of the column 2. A heating unit 23 heats the column 2 to desorb sample gas captured by the gas capturing unit 20. Sample gas desorbed from the gas capturing unit 20 is introduced into a cell 31. A light source unit 32 irradiates sample gas in the cell 31 with light. An analysis unit 3 analyzes sample gas based on an intensity change of light emitted by the light source unit 32.

Abstract: The disclosure aims to provide a composition capable of suppressing fluororesin agglomeration, which may lead to strands with a poor appearance, even when the proportion of the fluororesin is increased, and also aims to provide a molded article, a laminate, and a resin. The disclosure relates to a composition containing: a fluororesin A; and a resin B other than the fluororesin A, the resin B having a melt flow rate of 30 g/10 min or higher at a melting point +12° C., at least one of the fluororesin A or the resin B containing a group (I) represented by the following formula: wherein R1 and R2 are the same as or different from each other, are each hydrogen or an organic group, and optionally bond to each other to form a ring structure; and a double line composed of a solid line and a dotted line represents a single bond or a double bond.

Abstract: The present invention addresses the problem of providing a white blood cell capturing device that captures white blood cells with high efficiency while being unsusceptible to capturing other material.

Abstract: The present invention provides a cationic lipid that can be used as a nucleic acid delivery carrier with good intracellular dynamics, a lipid membrane structure containing the same, a nucleic acid-introducing agent and a pharmaceutical composition containing any of them, a method for introducing nucleic acid into cells or target cells, and a method for producing a cell medicine. A cationic lipid represented by the formula (1) (definitions of symbols in the formula are as described in the specification), a lipid membrane structure using the aforementioned cationic lipid, a nucleic acid-introducing agent and a pharmaceutical composition using the aforementioned cationic lipid or the aforementioned lipid membrane structure, a method for introducing nucleic acid into cells or target cells by using the aforementioned nucleic acid-introducing agent, and a method for producing a cell medicine by using the aforementioned nucleic acid-introducing agent.

Abstract: A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5? terminal side of the region, (c) one or more nucleotide analogs located on 3? terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

Abstract: A total primary combustion burner which includes a burner body with an air-fuel mixture chamber into which an air-fuel mixture of a fuel gas and primary air is supplied, a combustion plate portion covering an opening surface, which faces the air-fuel mixture chamber, of the burner body, and a backfire suppressing plate portion disposed opposite the combustion plate portion with a gap inside the air-fuel mixture chamber. The air-fuel mixture passing through the backfire suppressing plate portion ejects from the combustion plate portion and undergoes combustion. The total primary combustion burner is configured so that backfire can be suppressed as much as possible while suppressing pressure loss, even when using hydrogen as the fuel gas. The backfire suppressing plate portion has a sintered sheet obtained by sintering a laminate made by sintering an aggregate of metallic fibers or beads.

Abstract: The present invention aims to provide a novel compound that can be a component of boron drugs. The present invention provides a boronic acid-containing modified polyrotaxane, which is a polyrotaxane having a plurality of cyclodextrin molecules, a linear molecule that pierces the openings of the plurality of cyclodextrin molecules in a skewered manner, and blocking groups that are arranged at both ends of the linear molecule and prevent the cyclodextrin molecule from being separated from the linear molecule, in which at least a portion of the cyclodextrin molecules is bonded via a linker to a monovalent group derived from boronic acid or a derivative thereof.

Abstract: The present invention provides a method for producing nucleic acid-encapsulated lipid nanoparticles, which can encapsulate any nucleic acid with high efficiency and with ease. A method for producing nucleic acid-encapsulated lipid nanoparticles, including the following steps: a) a step of preparing a suspension of lipid nanoparticles not containing a nucleic acid, by mixing an alcohol solution containing ionic lipid, sterol and PEG lipid with an acidic buffer having a buffering action at pH 1 to 6.5, and b) a step of mixing, without lyophilization, the suspension of the lipid nanoparticles obtained in step a with an aqueous solution containing a nucleic acid and optionally containing 0 to 25 v/v % alcohol, and optionally incubating the mixture at 0 to 95° C. for 0 to 60 min to obtain nucleic acid-encapsulated lipid nanoparticles.

Abstract: A copper alloy bonded body composed of a plurality of members made of an age-hardenable copper alloy, the members diffusion-bonded to one another. The copper alloy bonded body has undergone solution annealing and an aging treatment, the content of beryllium in the age-hardenable copper alloy is 0.7% by weight or less, and (i) a bonding interface between the members has disappeared and/or (ii) a bonding interface between the members remains, and an oxide film at the bonding interface has a thickness of 0 nm or more and 5.0 nm or less.

Abstract: This method for producing a fiber-reinforced composite material includes: a fiber dispersion process of providing a fiber-dispersed resin by kneading a resin 10a with fibers 10b to disperse the fibers 10b in the resin 10a; and a molecular weight reduction process in which, while transporting the fiber-dispersed resin along an outer peripheral surface of a screw body 37 provided with a passage 88 inside, the fiber-dispersed resin passes from an inlet 91 of the passage 88 to an outlet 92 of the passage 88 and a shear force is applied to the fiber-dispersed resin by restricting the transport of the fiber-dispersed resin with a barrier unit 82 disposed between the inlet 91 and the outlet 92 of the passage 88 on the outer peripheral surface.

Abstract: The present invention provides lipid nanoparticles for delivering nucleic acid to peripheral blood mononuclear cells that can improve the efficiency of nucleic acid delivery to peripheral blood mononuclear cells, and a method for delivering nucleic acid to peripheral blood mononuclear cells by using same. Lipid nanoparticles for use in delivering a nucleic acid to a peripheral blood mononuclear cell, containing an ionic lipid represented by the formula (1), a phospholipid that is 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups have not less than 20 carbon atoms and at least one of the acyl groups is an alkenoyl group, cholesterol, and a dimyristoylglycerol PEG represented by the formula: CH2(OR6)—CH(OR7)—CH2(OR8) (symbols in the formula are as described in the specification), and a method for delivering a nucleic acids to a peripheral blood mononuclear cell by using same.